SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Secret_Agent_Man who started this subject4/19/2002 5:45:03 PM
From: IRWIN JAMES FRANKEL  Read Replies (1) of 508
 
Friday April 19, 5:03 pm Eastern Time
Press Release
SOURCE: InterMune, Inc.
InterMune to Release First Quarter 2002 Earnings on Wednesday, April 24, 2002
BRISBANE, Calif., April 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN - news) today announced that it will release its first quarter 2002 financial results on Wednesday, April 24, 2002 at 4:00 p.m. Eastern Daylight Time (EDT). To ensure full disclosure to all parties, InterMune will host a live earnings discussion conference call and webcast at 4:15 p.m. EDT that same day.

To access the live call or the three-day archive via the internet, please logon to intermune.com . Please logon to the Company's website at least 15 minutes prior to the start of the conference call to ensure adequate time for any software downloads that may be required to access the webcast. Alternatively, you may access the live teleconference by dialing 888-799-0528 (U.S.) or 706-634-0154 (international). A replay of the teleconference will be available approximately three hours after the call through 11:59 p.m. EDT, April 26, 2002. To access the replay, please call 1-800-642-1687 (U.S.) or 706-645-9291 (international), and enter the conference ID# 3797850.

About InterMune

InterMune, Inc., is a commercially driven biopharmaceutical company focused on the marketing, development and applied research of life-saving therapies for pulmonary disease, infectious disease and cancer. For additional information about InterMune, please visit www.intermune.com.

SOURCE: InterMune, Inc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext